Bausch Health Companies Inc. Payments of Debt Restructuring Costs
Bausch Health Companies Inc. (BHC) had Payments of Debt Restructuring Costs of $4.00 million as of 2018-06-01, per its 8-K filed 2021-05-04.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtRestructuringCosts · last filed 2021-05-04
- 2018-06-01: Payments of Debt Restructuring Costs $4.00M.
| Period end | Payments of Debt Restructuring Costs |
|---|---|
| 2018-06-01 | $4.00M 8-K · filed 2021-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |